Key Finding: Silo Pharma (NASDAQ: SILO) is a micro-cap developmental biopharmaceutical company advancing intranasal and implant-based therapeutics targeting PTSD, chronic pain, and CNS disorders, with recent clinical and IP progress amid highly volatile stock performance and ongoing Nasdaq compliance efforts.
Company Overview
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, chronic pain, Alzheimer's, and other CNS diseases. Its lead candidate is SPC-15, an intranasal treatment for PTSD. Other programs include SP-26 (ketamine implant for pain/fibromyalgia), SPC-14 (Alzheimer's), and SPU-16 (MS peptide). Research collaborations include Columbia University, Medspray Pharma BV, and University of Maryland, Baltimore.
Headquarters: Sarasota, Florida Employees: Small team (developmental stage, exact count not publicly detailed in recent filings) Website:silopharma.com | IR Site
Pipeline Highlights (as of mid-2026)
SPC-15 (PTSD): Positive stability data; drug-device robustness study underway with Resyca; advancing toward FDA Type C meeting and potential first-in-human trial.
SP-26 (Chronic Pain/Fibromyalgia): Positive initial PK/safety/tolerability study completed.
IP: Multiple patents and provisional filings, including U.S. patent for intranasal PTSD treatment and ibogaine-based TBI therapeutic.
Company History
Incorporated in 2010 as Uppercut Brands, Inc.; name changed to Silo Pharma, Inc. in September 2020. The company pivoted to biopharmaceutical development with a focus on psychedelic-assisted and novel formulations. It has pursued collaborations with academic institutions and advanced its IP portfolio through patents and filings. The company has also explored a cryptocurrency treasury strategy via agreements with Fireblocks.
Interpretation: The name change and pivot reflect a strategic shift from prior branding activities to high-risk, high-reward biotech R&D typical of micro-cap developmental firms.
Recent News (2025–2026)
July 2026: Subsidiary QwikAgents advances enterprise AI agent platform via NVIDIA Developer Program.
June 2026: Engages Resyca for SPC-15 drug-device robustness study ahead of FDA Type C meeting.
June 2026: Reports positive stability data for SPC-15, advancing toward first-in-human trial.
June 2026: Regains compliance with Nasdaq minimum bid price requirement.
Feb 2026: Board authorizes $1M share repurchase program.
2025: Multiple IP advancements (U.S. patent for intranasal PTSD treatment, provisional filings); positive SP-26 study results; $2.5M registered direct offering; Fireblocks crypto treasury agreements; earnings reports showing continued losses.
Note: News flow is primarily company press releases; independent analyst coverage appears limited.
Stock Performance
As of July 9, 2026 (intraday): ~$7.34 (+8.19% on the day), Market Cap ≈ $8.28M, 52-week range $3.32–$15.15. Highly volatile micro-cap stock with significant long-term decline from historical highs. Average daily volume ~150K–200K shares. EPS (TTM) ≈ -$5.85; Revenue (TTM) ≈ $72K.
Metric
Value (approx. July 2026)
Current Price
$7.34
Market Cap
$8.28M
52-Week High/Low
$15.15 / $3.32
YTD Return
+~44% (recent data)
1-Year Return
Variable (~+21% in one snapshot)
5-Year Return
Strongly negative (≈ -95%)
P/E Ratio
N/A (unprofitable)
Performance Context
Facts: Stock has experienced extreme volatility typical of developmental biotechs; regained Nasdaq compliance in June 2026 after bid price issues; conducted equity offerings and repurchase authorization.
Interpretations: Recent price swings likely tied to clinical updates, financing news, and broader market sentiment toward psychedelics/biotech. Long-term underperformance reflects high burn rate and pre-revenue status.
Uncertainties & Limitations: Share price and volume data are snapshots and fluctuate rapidly; historical performance includes reverse splits or adjustments not detailed here; no analyst price targets widely available. Data sourced from public market feeds as of early July 2026.